Perrigo (PRGO) Amortization of Deferred Charges (2015 - 2026)
Perrigo's (PRGO) quarterly Amortization of Deferred Charges came in at -$4.9 million in Q1 2026, up 23.44% year-on-year from -$4.0 million in Q1 2025, and up 10.91% on a QoQ basis from -$5.5 million in Q4 2025.
Perrigo (PRGO) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Perrigo (PRGO) has 6 years of Amortization of Deferred Charges data on file, last reported at -$4.9 million in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 23.44% year-over-year to -$4.9 million in Q1 2026; TTM through Mar 2026 was -$35.7 million, a 4.29% increase from a year earlier, with the FY2025 full-year figure at -$23.8 million, down 135.64% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at -$4.9 million, up from -$5.5 million in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for PRGO reached as high as -$4.9 million in Q1 2026 and fell as low as -$18.9 million in Q4 2024.
- Historically, Amortization of Deferred Charges has averaged -$8.9 million across 3 years, with a median of -$5.9 million in 2025.
- Across the five-year window, Amortization of Deferred Charges soared 70.9% in 2025 and advanced 23.44% in 2026, its largest moves.
- Year by year, Amortization of Deferred Charges stood at -$18.9 million in 2024, then jumped by 70.9% to -$5.5 million in 2025, then increased by 10.91% to -$4.9 million in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were -$4.9 million in Q1 2026, -$5.5 million in Q4 2025, and -$6.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -4.90 Mn |
| Mar 28, 2026 | -4.90 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Mar 29, 2025 | -6.40 Mn |
| Mar 29, 2025 | -6.40 Mn |
| Dec 31, 2024 | -18.90 Mn |
| Dec 31, 2024 | -18.90 Mn |
| Sep 30, 2017 | -6.60 Mn |
| Sep 30, 2017 | -6.60 Mn |
| Jul 1, 2017 | -5.40 Mn |
| Jul 1, 2017 | -5.40 Mn |
| Apr 1, 2017 | -6.40 Mn |
| Apr 1, 2017 | -6.40 Mn |
| Jul 2, 2016 | -9.40 Mn |
| Jul 2, 2016 | -9.40 Mn |
| Apr 2, 2016 | -6.70 Mn |
| Apr 2, 2016 | -6.70 Mn |
| Sep 26, 2015 | -8.50 Mn |
| Sep 26, 2015 | -8.50 Mn |